LISTING OF CLAIMS

1. (currently amended) An aqueous based pharmaceutical composition for ~~pharmaceutical use~~ oral administration comprising an aqueous vehicle and a Cyclohexylamine selected from neramexane and pharmaceutically acceptable salts thereof,

   wherein the composition is free of preservatives.

2. (previously presented) The composition of claim 1, wherein the concentration of the Cyclohexylamine derivative is at least about 1 mg/mL.

3. (previously presented) The composition of claim 1, wherein the concentration of the Cyclohexylamine derivative has an overall strength of about 2 mg/mL.

4. (currently amended) The composition of claim 1, wherein the concentration of the Cyclohexylamine ~~or Aminoadamantane~~ derivative has an overall strength of about 4 mg/mL.

5. (previously presented) The composition of claim 1, wherein the concentration of the Cyclohexylamine derivative has an overall strength of about 5 mg/mL.

6. (previously presented) The composition of claim 1, wherein the concentration of the Cyclohexylamine derivative has an overall strength of about 10 mg/mL.

7. (previously presented) The composition of claim 1, wherein the concentration of the Cyclohexylamine derivative has an overall strength of about 20 mg/mL.

8. (canceled)

9. (canceled)

10. (canceled)

11. (canceled)

12. (canceled)

13. (previously presented) The composition of claim 1, wherein the Cyclohexylamine derivative is neramexane mesylate.

14. (previously presented) The composition of claim 1, wherein the concentration of neramexane or of the pharmaceutically acceptable salt thereof is in the range from about 2 mg/mL to about 100 mg/mL.

15. (previously presented) The composition of claim 14, wherein the concentration of neramexane or of the pharmaceutically acceptable salt thereof is in the range from about 5 mg/mL to about 10 mg/mL.

16. (previously presented) The composition of claim 1, wherein the aqueous vehicle is purified water, USP.

17. (previously presented) The composition of claim 1, further comprising one or more sweeteners present in an amount ranging from about 10 mg/ml to about 500 mg/ml.

18. (previously presented) The composition of claim 17, wherein the sweetener is selected from the group consisting of sorbitol, sucrose, saccharin sodium, aspartame and N & A Flavor Enhancer.

19. (previously presented) The composition of claim 17, wherein the sweetener is sorbitol.

20. (previously presented) The composition of claim 1, further comprising a solubilizer selected from the group consisting of propylene glycol,

polyethylene glycol, and glycerin present in an amount ranging from about 8% to about 12% w/v.

21. (previously presented) The composition of claim 20, wherein the solubilizer is glycerin.

22. (previously presented) The composition of claim 21, wherein the glycerin is present in an amount ranging from about 8% w/v to about 12% w/v solution.

23. (withdrawn) The composition of claim 1, further comprising one or more excipients selected from the group consisting of flavors, flavor enhancers, taste masking agents, thickeners, stabilizers, and crystallization inhibitors.

24. (withdrawn) The composition of claim 23, wherein the flavor is selected from the group consisting of natural peppermint #104, artificial cherry #10641, artificial grape #255, orange N&A 583K and artificial grape bubble gum # 998.

25. (withdrawn) The composition of claim 23, wherein the flavor is present in a concentration ranging from about 0.05% to about 2.0%.

26. (currently amended) The composition of claim 1, further comprising another active compound effective in the management of CNS-related conditions or diseases, wherein said active compound is not an NMDA receptor antagonist selected from neramexane and pharmaceutically acceptable salts thereof.

27. (withdrawn) The composition of claim 1, further comprising a buffer to adjust pH of the solution.

28. (withdrawn) The composition of claim 27, wherein the buffer is selected from the group consisting of citric acid, sodium citrate, acetic acid,

sodium acetate, sodium phosphate, and combinations of two or more of the foregoing.

29. (withdrawn) The composition of claim 27, wherein the buffer is a combination of citric acid and sodium citrate.

30. (withdrawn) The composition of claim 27, wherein the buffer is present an amount ranging from about 1 mg/ml to about 10 mg/ml.

31. (withdrawn) The composition of claim 27, wherein the pH is adjusted to between about 4.5 to about 6.5.

32. (withdrawn) The composition of claim 27, wherein the pH is adjusted to about 5.5.

33. (canceled)

34. (canceled)

35. (canceled)

36. (canceled)

37. (canceled)

38. (canceled)

39. (previously presented) A container comprising a plurality of doses of a Cyclohexylamine derivative selected from neramexane and pharmaceutically acceptable salts thereof, wherein the Cyclohexylamine derivative is formulated as a composition of claim 1.

40. (previously presented) The container of claim 39, wherein the volume of the composition is in the range from about 5 mL to about 1,000 mL.

41. (previously presented) The container of claim 39, further comprising a means for measuring a volume in the range from about 0.5 to about 10 mL.

42. (canceled)

43. (canceled)

44. (currently amended) A composition of claim 1 comprising

~~a.~~ Neramexane mesylate and
~~b.~~ Purified Water, USP, QS.

45. (canceled)

46. (canceled)

47. (canceled)

48. (canceled)

49. (canceled)

50. (canceled)

51. (canceled)

52. (canceled)

53. (canceled)

54. (canceled)

55. (canceled)